COLOSSAL'S 'DE-EXTINCTION' BETS BIG ON GENETIC ENGINEERING
INDUSTRY DESK■ 1 MIN READ
SAT, MAY 23, 2026■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE
Dallas-based biotech startup Colossal has raised hundreds of millions from venture capitalists, the CIA, and Peter Thiel to resurrect extinct animals. The company's approach uses genetic engineering rather than cloning ancient DNA.
Colossal's ambitions span woolly mammoths, Tasmanian tigers, and dire wolves—though the marketing term "de-extinction" oversimplifies the science. The startup doesn't recover lost creatures from fossilized DNA. Instead, it modifies living animals' genomes to recreate extinct species' traits.
The 2025 dire wolf reveal exemplified this strategy: the presented animals were gray wolves with edited genes, not recreated dire wolves. This genetic approach sidesteps technical barriers that make true cloning from ancient DNA impractical.
The venture has attracted serious backing, signaling investor confidence in synthetic biology applications. However, the gap between genetic modification and true species resurrection remains substantial. Colossal's work advances biotechnology capabilities while raising questions about ecosystem integration and project timelines.
The startup represents a growing sector betting that genetic engineering can solve extinction—even if the science differs sharply from popular perception.
■ SOURCES
► The Verge■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE
■ MORE FROM THE STARTUPS DESK
Triomics, an AI platform automating data-heavy tasks for oncologists, secured $22M in Series B funding. The raise follows a $15M Series A in 2024.
12H AGO— AI Desk
Xcena secured $135 million in Series B funding at a $570 million valuation for its MX1 chip, which handles data orchestration and KV cache management directly within memory modules.
12H AGO— AI Desk
Pittsburgh-based Gray Swan, which stress-tests AI models for frontier labs, secured $40M in Series A funding at a $200M valuation. The round was co-led by Wing VC and Madrona.
20H AGO— AI Desk
H1, a healthcare SaaS startup, secured $40 million in funding from CVS Health. The investment signals continued investor confidence in specialized software platforms despite AI disruption concerns.
YESTERDAY— Industry Desk